Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

January 8, 2009

Primary Completion Date

April 2, 2010

Study Completion Date

April 2, 2010

Conditions
Eosinophilic Esophagitis (EoE)
Interventions
DRUG

budesonide

oral suspension

DRUG

placebo

oral suspension matching budesonide

Trial Locations (20)

19104

Children's Hospital of Philadelphia, Philadelphia

23219

Virginia Commonwealth University, Medical College of Virginia, Richmond

23507

Children's Hospital of the King's Daughters, Norfolk

24013

Carilion Pediatric Gastroenterology, Roanoke

29615

Children's Center for Digestive Health, Greenville

30322

Emory University-Emory Children's Center, Atlanta

30342

Children's Center for Digestive Healthcare, Atlanta

46202

Riley Hospital for Children, Indianapolis

60068

Center for Children's Digestive Health, Park Ridge

60614

Children's Memorial Hospital, Chicago

68105

The Center for Human Nutrition, Omaha

80045

The Children's Hospital, Aurora

85006

Phoenix Children's Hospital, Phoenix

89109

Pediatric Gastroenterology and Nutrition Associates, Las Vegas

92123

Rady Children's Hospital, San Diego

92868

Children's Hospital of Orange County, Orange

94305

Stanford University Medical Center, Palo Alto

02111

Tufts Medical Center, Boston

02115

Children's Hospital Boston, Boston

08330

South Jersey Pediatric Gastroenterology, Mays Landing

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY

NCT00762073 - Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis | Biotech Hunter | Biotech Hunter